Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
It is very uncertain whether four‐food elimination diet with omeprazole changes withdrawals due to adverse events at 8 to 12 weeks compared with omeprazole (very low certainty).
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether radiotherapy changes adverse events, reported as "negative experiences" compared with botulinum toxin (very low certainty).
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy (range 30 to 36 months compared with alkylating agents ± steroids (very low certainty).
It is very uncertain whether chinese herbal medicine (CHM) plus follicle aspiration plus… changes ovarian hyperstimulation syndrome (adverse events) compared with follicle aspiration plus ovulation induction (very low certainty).
It is very uncertain whether summary of findings table ‐ More time changes serious adverse events/death: medium‐term outcomes compared with less time (very low certainty).
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).